| Current progress of siRNA/shRNA therapeutics in clinical trials JC Burnett, JJ Rossi, K Tiemann Biotechnology journal 6 (9), 1130-1146, 2011 | 623 | 2011 |
| RNAi‐based therapeutics–current status, challenges and prospects K Tiemann, JJ Rossi EMBO molecular medicine 1 (3), 142-151, 2009 | 354 | 2009 |
| Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells J Zhou, K Tiemann, P Chomchan, J Alluin, P Swiderski, J Burnett, ... Nucleic acids research 41 (7), 4266-4283, 2013 | 87 | 2013 |
| Antisense 2′-deoxy, 2′-fluoroarabino nucleic acid (2′ F-ANA) oligonucleotides: in vitro gymnotic silencers of gene expression whose potency is enhanced by fatty acids N Souleimanian, GF Deleavey, H Soifer, S Wang, K Tiemann, MJ Damha, ... Molecular Therapy-Nucleic Acids 1, 2012 | 79 | 2012 |
| MicroRNAs act complementarily to regulate disease-related mRNA modules in human diseases S Chavali, S Bruhn, K Tiemann, P Sætrom, F Barrenäs, T Saito, K Kanduri, ... Rna 19 (11), 1552-1562, 2013 | 58 | 2013 |
| Retinoic acid and androgen receptors combine to achieve tissue specific control of human prostatic transglutaminase expression: a novel regulatory network with broader significance GC Rivera-Gonzalez, AP Droop, HJ Rippon, K Tiemann, D Pellacani, ... Nucleic acids research 40 (11), 4825-4840, 2012 | 40 | 2012 |
| Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial F Chiuppesi, JA Zaia, PH Frankel, R Stan, J Drake, B Williams, AM Acosta, ... The Lancet Microbe 3 (4), e252-e264, 2022 | 36 | 2022 |
| Dual-targeting siRNAs K Tiemann, B Höhn, A Ehsani, SJ Forman, JJ Rossi, P Sætrom Rna 16 (6), 1275-1284, 2010 | 32 | 2010 |
| Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis K Tiemann, C Garri, SB Lee, PD Malihi, M Park, RM Alvarez, LP Yap, ... Oncogene 38 (16), 3003-3018, 2019 | 29 | 2019 |
| A link between integral membrane protein expression and simulated integration efficiency SS Marshall, MJM Niesen, A Müller, K Tiemann, SM Saladi, RP Galimidi, ... Cell Reports 16 (8), 2169-2177, 2016 | 21 | 2016 |
| JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. MP Kani K, Garri C, Tiemann K, Malihi PD, Punj V, Nguyen AL, Lee J, Hughes ... Mol Cancer Ther 16 (8), 1645-1657, 2017 | 20 | 2017 |
| Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines K Tiemann, JV Alluin, A Honegger, P Chomchan, S Gaur, Y Yun, ... Leukemia & lymphoma 52 (11), 2148-2154, 2011 | 19 | 2011 |
| Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2) C Garri, S Howell, K Tiemann, A Tiffany, F Jalali-Yazdi, MM Alba, JE Katz, ... Oncotarget 9 (44), 27363, 2018 | 9 | 2018 |
| RNA aptamers against BAFF-R as cell-type specific delivery agents and methods for their use J Rossi, K Tiemann, J Zhou, B Vallazza US Patent 9,006,416, 2015 | 3 | 2015 |
| Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study LE Budde, MM Del Real, JH Baird, L Chen, JY Song, S Kambhampati, ... Blood 142, 221, 2023 | 1 | 2023 |
| Assessment of resistance to tyrosine kinase inhibitors by an interrogation of signal transduction pathways by antibody arrays K Tiemann, C Garri, J Wang, L Clarke, K Kani JoVE (Journal of Visualized Experiments), e57779, 2018 | 1 | 2018 |
| RNA aptamers against BAFF-R as cell-type specific delivery agents and methods for their use J Rossi, K Tiemann, J Zhou, B Vallazza US Patent 9,353,374, 2016 | 1 | 2016 |
| Process Development and Manufacturing: CUSTOM CLOSED-SYSTEM PLATFORM FOR MANUFACTURE OF LENTIVIRAL-TRANSDUCED HEMATOPOIETIC STEM PROGENITOR CELLS FOR GENE THERAPY M Torres-Coronado, A Gardner, X Li, D Browning, K Tiemann, J Zaia, ... Cytotherapy 24 (5), S22, 2022 | | 2022 |
| CUSTOM CLOSED-SYSTEM PLATFORM FOR MANUFACTURE OF LENTIVIRAL-TRANSDUCED HEMATOPOIETIC STEM PROGENITOR CELLS FOR GENE THERAPY M Torres-Coronado, A Gardner, X Li, D Browning, K Tiemann, J Zaia, ... CYTOTHERAPY 24 (5), S22-S22, 2022 | | 2022 |
| Improvement of Integral Membrane Protein Expression via Optimization of Simulated Integration Efficiency SS Marshall California Institute of Technology, 2018 | | 2018 |
John C. BurnettAssociate Professor at University of Miami and Sylvester Comprehensive Cancer CenterVerified email at miami.edu
